IMPORTANT SAFETY INFORMATION:
NEXAVAR is contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of NEXAVAR. Continue reading below

Nexavar in Advanced RCC

Progression-free survival (PFS) results

In the TARGET trial, NEXAVAR-treated patients (n=384) experienced a median PFS of 5.5 months, compared with 2.8 months for patients receiving placebo (n=385; HR=0.44; 95% CI, 0.35-0.55; P<0.000001).

File Text Image

TARGET (Treatment Approaches in Renal Cancer Global Evaluation Trial): A randomized, double-blind, placebo-controlled, multicenter, Phase III study in patients with advanced RCC who had received 1 prior systemic therapy (N=903).2
HR=hazard ratio; CI=confidence interval.
*Independently assessed data.

  • NEXAVAR nearly doubled PFS1
  • Patients receiving NEXAVAR showed a 56% reduction in risk of progression or death

Indications

NEXAVAR is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC).

NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Important Safety Information

For important risk and use information about NEXAVAR, please see the full Prescribing Information.

INDICATION and IMPORTANT SAFETY INFORMATION for STIVARGA® (regorafenib)

For important risk and use information about STIVARGA, please see the full Prescribing Information including the Boxed Warning.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

REFERENCES:

1. NEXAVAR Prescribing Information. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc. 2. Escudier B, Eisen T, Stadler WM, et al; for TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134.